A Dartmouth College investigation has concluded that H. Gilbert Welch, MD, MPH, a prominent healthcare policy researcher, committed research misconduct in connection with a breast cancer paper published in The New England Journal of Medicine in 2016; a Boston University endocrinologist, Michael Holick, MD, who had a crucial role in drafting national vitamin D guidelines, has benefitted from the industry in the amount of hundreds of thousands of dollars; 24 states have passed 37 bills this year to curb rising prescription drug costs as bipartisan efforts are forcing pharmaceutical companies to disclose and justify price increases.
A Dartmouth College investigation has concluded that H. Gilbert Welch, MD, MPH, a prominent healthcare policy researcher, committed research misconduct in connection with a breast cancer paper published in The New England Journal of Medicine (NEJM) in 2016. NEJM is not retracting the paper, saying it is an issue of authorship dispute. According to STAT News and Retraction Watch, Welch plagiarized material from a Dartmouth colleague and another researcher at a different institution, according to a June letter from the college’s interim provost. Welch has denied the allegations.
A Boston University endocrinologist, Michael Holick, MD, who had a crucial role in drafting national vitamin D guidelines, has benefitted from the industry in the amount of hundreds of thousands of dollars, according to a Kaiser Health News investigation. The list includes drugmakers, the indoor-tanning business, and Quest Diagnostics. Holick helped create a billion-dollar vitamin D sales and testing industry, with supplement sales rising to $936 million last year, a 9-fold increase over the previous decade. Physicians have embraced his message, ordering more than 10 million vitamin D tests for Medicare patients in 2016, up 547% since 2007, at a cost of $365 million.Twenty-four states have passed 37 bills this year to curb rising prescription drug costs as bipartisan efforts are forcing pharmaceutical companies to disclose and justify price increases, The New York Times reported. Drug makers are challenging the state laws as a violation of their constitutional rights. States are also trying to regulate pharmacy benefit managers. New York, Utah, Ohio, Connecticut, Nevada, California, Oklahoma, and Maryland are all trying different approaches in an effort to reduce out-of-pocket costs for consumers struggling to afford drugs that often cost thousands of dollars a month.
Real-World Study Reveals Key Insights into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Gene, Light Therapy Combo Shows Promise Against Prostate Cancer Cells in Proof-of-Concept Study
April 18th 2024In their preclinical model, the researchers found efficacy both in vitro and in vivo by using CRISPR-Cas9 to mimic porphyria and combining the technology with light therapy.
Read More
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen
Collecting SDOH Data Can Assess Risk of Medical Nonadherence, Improve HEI and Star Ratings
April 18th 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, a panel of presenters explored changes coming to Medicare that incorporate social determinants of health (SDOH) data to improve patient and health system outcomes.
Read More